Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer
Year: 2024
Type: other
Abstract: Gene expression analysis comparing immune infiltration in the mRCC treatment-naïve cohort and mRCC cohort from the daratumumab study (prior to treatment) and showing significant reduction across immune cell subtypes in heavily pretreated patients. Tx, treatment.
Authors: Matthew T. Campbell, Amishi Y. Shah, Pavlos Msaouel, Nizar M. Tannir, Arlene O. Siefker-Radtke, Ashish M. Kamat, Neema Navai, Colin P.N. Dinney, Priya Rao, Charles C. Guo, Rahul A. Sheth, Aradhana M. Venkatesan, Rebecca S. Tidwell, Shalini S. Yadav, Aidi Gu, Hong Chen, Marc Macaluso, Fei Duan, Sreyashi Basu, Sonali Jindal, Padmanee Sharma
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402575420